Heart rate as a therapeutic target in heart failure?

被引：10
|
作者：
Tavazzi, L [1 ]
机构：
[1] Inst Care Res, Dept Cardiol, Policlin San Matteo, Pavia, Italy
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 2003年 / 5卷 / 0G期
关键词：
heart rate; heart failure; I-f channel; I-f channel antagonist; ivabradine;
D O I：
10.1016/S1520-765X(03)90003-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A common finding in all clinical trials on heart failure is a negative correlation between heart rate and duration of life. In several studies this was found in both patients taking and those not taking beta-blocker agents. In postinfarct patients increasing mortality with increasing heart rate was found in the absence and in the presence of left ventricular dysfunction. Moreover beneficial effects of neurohormonal modulators were found to be greater in heart failure patients with higher heart rate. Thus heart rate can be considered a target for medical intervention, and therapeutic attempts focused on direct control of heart rate have a good rationale. (C) 2003 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：G15 / G18
页数：4
相关论文
共 50 条
  • [31] Heart rate reduction in heart failure: ivabradine or beta blockers?
    Maya Guglin
    Heart Failure Reviews, 2013, 18 : 517 - 528
  • [32] From ischaemia to heart failure: Heart rate - Actor or stamper?
    Lechat, P
    THERAPIE, 2004, 59 (05): : 485 - 489
  • [33] Heart Rate As a Biomarker in Heart Failure: Role of Heart Rate Lowering Agents
    Shaaya, Ghazwan
    Al-Khazaali, Ali
    Arora, Rohit
    AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (05) : E532 - E539
  • [34] Inhibition of Activin A is the Novel Therapeutic Target for Heart Failure
    Fukushima, Noritoshi
    Matsuura, Katsuhisa
    Akazawa, Hiroshi
    Honda, Atsushi
    Nagai, Toshio
    Takahashi, Toshinao
    Seki, Akiko
    Murasaki, Kagari
    Shimizu, Tatsuya
    Okano, Teruo
    Komuro, Issei
    Hagiwara, Nobuhisa
    CIRCULATION, 2011, 124 (21)
  • [35] GRK2 as a therapeutic target for heart failure
    Cannavo, Alessandro
    Komici, Klara
    Bencivenga, Leonardo
    D'amico, Maria Loreta
    Gambino, Giuseppina
    Liccardo, Daniela
    Ferrara, Nicola
    Rengo, Giuseppe
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (01) : 75 - 83
  • [36] The neurometabolic axis: A novel therapeutic target in heart failure
    Chakraborty, Praloy
    Po, Sunny S.
    Scherlag, Benjamin J.
    Dasari, Tarun W.
    LIFE SCIENCES, 2023, 333
  • [37] Does a Target Dose or a Target Heart Rate Matter to Outcomes When Prescribing β-Blockers to Patients With Chronic Heart Failure?
    Packer, Milton
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2018, 11 (04):
  • [38] Protein kinase C in heart failure: a therapeutic target?
    Palaniyandi, Suresh Selvaraj
    Sun, Lihan
    Batista Ferreira, Julio Cesar
    Mochly-Rosen, Daria
    CARDIOVASCULAR RESEARCH, 2009, 82 (02) : 229 - 239
  • [39] Uric acid in heart failure: a biomarker or therapeutic target?
    Kaufman, Marc
    Guglin, Maya
    HEART FAILURE REVIEWS, 2013, 18 (02) : 177 - 186
  • [40] Sympathetic activation in heart failure:: A target of therapeutic approaches
    Schnabel, P
    Böhm, M
    ZEITSCHRIFT FUR KARDIOLOGIE, 1999, 88 : 5 - 11
12345